2023 World Conference on Lung Cancer (Posters)-EP08.02. Neoadjuvant Immunochemotherapy Combined with Probiotic Supplements in Stage IIB-IIIB NSCLC: A Real-World Prospective Study

EP08.02. Neoadjuvant Immunochemotherapy Combined with Probiotic Supplements in Stage IIB-IIIB NSCLC: A Real-World Prospective Study - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the potential effects of combining neoadjuvant immunochemotherapy and probiotic supplements as a therapeutic strategy in patients with non-small cell lung cancer (NSCLC). The study enrolled 43 patients with stage IIB to IIIB NSCLC who received 3 cycles of nivolumab plus platinum-based chemotherapy and daily oral administration of probiotic supplements. The primary endpoint of the study was pathological complete response (pCR), and the secondary endpoint was progression-free survival (PFS). The gut microbiota of patients from the pCR and non-pCR groups was analyzed using metagenomics sequencing. <br /><br />The results showed that 53.5% of the patients achieved pCR, and the median PFS at 19 months was 93.0%. The incidence of severe treatment-related adverse events (trAE) was low, with only 14.0% of patients experiencing trAE of grade 3. None of the adverse events were associated with surgery delays or deaths.<br /><br />The analysis of gut microbiota showed that the beta diversity index was elevated after receiving neoadjuvant immunochemotherapy plus probiotic supplements. The chao1 index remained similar. The microbial structures at the species level significantly varied between the pCR and non-pCR groups. There were 81 differentially abundant microbial species before treatment and 83 after treatment between the two groups, with three overlapping species.<br /><br />Overall, the study concluded that patients with stage IIB to IIIB NSCLC who received neoadjuvant immunochemotherapy plus probiotic supplements had a high pCR rate, a long PFS, and a low incidence of severe trAE. The analysis suggested that gut microbiota may be involved in the response to neoadjuvant immunochemotherapy in NSCLC, which requires further investigation.

Asset Subtitle

Min Li

Meta Tag

Speaker Min Li

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

neoadjuvant immunochemotherapy

probiotic supplements

non-small cell lung cancer

NSCLC

pathological complete response

pCR

progression-free survival

PFS

gut microbiota

metagenomics sequencing